Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.21
(2.56%)
CNY 3.21
(2.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -199.71 Million CNY | -30.4% |
| 2022 | -153.15 Million CNY | 62.11% |
| 2021 | -404.18 Million CNY | 39.07% |
| 2020 | -663.38 Million CNY | -488.82% |
| 2019 | 170.61 Million CNY | 162.23% |
| 2018 | -274.14 Million CNY | 49.56% |
| 2017 | -543.53 Million CNY | -140.95% |
| 2016 | -225.58 Million CNY | -199.33% |
| 2015 | -75.36 Million CNY | 82.88% |
| 2014 | -440.14 Million CNY | 23.27% |
| 2013 | -573.6 Million CNY | 35.14% |
| 2012 | -884.4 Million CNY | -1.32% |
| 2011 | -872.89 Million CNY | -1797.74% |
| 2010 | -45.99 Million CNY | -130.79% |
| 2009 | -19.93 Million CNY | -1093.5% |
| 2008 | -1.66 Million CNY | -122.15% |
| 2007 | 7.53 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -147.11 Million CNY | 41.77% |
| 2024 Q1 | -252.66 Million CNY | -26.51% |
| 2024 Q3 | -363.94 Million CNY | -147.38% |
| 2023 Q3 | -356.85 Million CNY | -26.03% |
| 2023 Q2 | -283.14 Million CNY | -92.03% |
| 2023 Q1 | -147.44 Million CNY | 3.72% |
| 2023 Q4 | -199.71 Million CNY | 44.04% |
| 2023 FY | -199.71 Million CNY | -30.4% |
| 2022 FY | -153.15 Million CNY | 62.11% |
| 2022 Q3 | -164.86 Million CNY | 54.6% |
| 2022 Q4 | -153.15 Million CNY | 7.1% |
| 2022 Q1 | -445.59 Million CNY | -10.24% |
| 2022 Q2 | -363.16 Million CNY | 18.5% |
| 2021 Q4 | -404.18 Million CNY | 30.12% |
| 2021 FY | -404.18 Million CNY | 39.07% |
| 2021 Q1 | -411.77 Million CNY | 37.93% |
| 2021 Q2 | -466.55 Million CNY | -13.3% |
| 2021 Q3 | -578.37 Million CNY | -23.97% |
| 2020 Q4 | -663.38 Million CNY | -11.76% |
| 2020 Q2 | -643.55 Million CNY | -185.06% |
| 2020 Q1 | -225.75 Million CNY | -232.32% |
| 2020 FY | -663.38 Million CNY | -488.82% |
| 2020 Q3 | -593.57 Million CNY | 7.77% |
| 2019 Q3 | 143.33 Million CNY | 72.65% |
| 2019 Q2 | 83.02 Million CNY | 278.67% |
| 2019 FY | 170.61 Million CNY | 162.23% |
| 2019 Q4 | 170.61 Million CNY | 19.03% |
| 2019 Q1 | -46.46 Million CNY | 83.05% |
| 2018 FY | -274.14 Million CNY | 49.56% |
| 2018 Q1 | -278.4 Million CNY | 48.78% |
| 2018 Q2 | -283.27 Million CNY | -1.75% |
| 2018 Q3 | -317.82 Million CNY | -12.2% |
| 2018 Q4 | -274.14 Million CNY | 13.74% |
| 2017 Q1 | -212.24 Million CNY | 5.91% |
| 2017 Q4 | -543.53 Million CNY | -160.72% |
| 2017 Q3 | -208.47 Million CNY | 14.63% |
| 2017 Q2 | -244.18 Million CNY | -15.05% |
| 2017 FY | -543.53 Million CNY | -140.95% |
| 2016 Q2 | -238.16 Million CNY | -806.25% |
| 2016 Q1 | -26.27 Million CNY | 65.13% |
| 2016 FY | -225.58 Million CNY | -199.33% |
| 2016 Q4 | -225.58 Million CNY | -40.34% |
| 2016 Q3 | -160.74 Million CNY | 32.51% |
| 2015 Q1 | -313.46 Million CNY | 28.78% |
| 2015 FY | -75.36 Million CNY | 82.88% |
| 2015 Q4 | -75.36 Million CNY | 64.93% |
| 2015 Q3 | -214.91 Million CNY | -9.78% |
| 2015 Q2 | -195.77 Million CNY | 37.55% |
| 2014 Q1 | -555.08 Million CNY | 3.23% |
| 2014 FY | -440.14 Million CNY | 23.27% |
| 2014 Q4 | -440.14 Million CNY | 1.78% |
| 2014 Q3 | -448.11 Million CNY | 14.26% |
| 2014 Q2 | -522.66 Million CNY | 5.84% |
| 2013 Q4 | -573.6 Million CNY | 17.18% |
| 2013 FY | -573.6 Million CNY | 35.14% |
| 2013 Q2 | -839.03 Million CNY | 2.41% |
| 2013 Q3 | -692.6 Million CNY | 17.45% |
| 2013 Q1 | -859.78 Million CNY | 2.78% |
| 2012 FY | -884.4 Million CNY | -1.32% |
| 2012 Q1 | -851.1 Million CNY | 2.5% |
| 2012 Q2 | -830.82 Million CNY | 2.38% |
| 2012 Q3 | -852.67 Million CNY | -2.63% |
| 2012 Q4 | -884.4 Million CNY | -3.72% |
| 2011 Q2 | -844.09 Million CNY | 7.08% |
| 2011 Q3 | -853.57 Million CNY | -1.12% |
| 2011 FY | -872.89 Million CNY | -1797.74% |
| 2011 Q4 | -872.89 Million CNY | -2.26% |
| 2011 Q1 | -908.45 Million CNY | -1875.05% |
| 2010 Q2 | -71.32 Million CNY | 0.0% |
| 2010 FY | -45.99 Million CNY | -130.79% |
| 2010 Q4 | -45.99 Million CNY | 0.0% |
| 2009 FY | -19.93 Million CNY | -1093.5% |
| 2008 FY | -1.66 Million CNY | -122.15% |
| 2007 FY | 7.53 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 7.24 Billion CNY | 102.755% |
| Realcan Pharmaceutical Group Co., Ltd. | 1.76 Billion CNY | 111.325% |